SU-F-P-50: Performance Evaluation of Optically Stimulated Luminescence (OSL) NanoDots in Therapy and Imaging In-Vivo Dose Measurement During Patient Treatment




This study was designed to evaluate the performance of optically stimulated Luminescence (OSL) nanoDots as in-vivo dosimeter. For the measurements of surface doses as well as scattered plus leakage doses, nanoDots were used during the setup verification as well as during the treatment delivery.


For a total seven patients undergoing radiotherapy by volumetric modulated arc therapy, surface doses from image guidance and scattered plus leakage doses from treatment delivery were measured. Two sets of calibration curves were generated – one for therapy and another for imaging. Two different nanoDots were used for imaging and therapy doses. Imaging nanoDots were placed at the isocenter only at the time of CBCT and therapy nanoDots were placed at 25 cm away from the isocenter (either in cranial or in caudal direction) only at the time of treatment delivery. During the entire course, nanoDots were placed at the same measurement points. NanoDots were read after 15 minutes of their exposure. For the next fraction, nanoDots were corrected for the residual doses from the previous fractions.


Measured surface doses during imaging were 0.14±0.32 cGy, 0.11±0.04 cGy, 0.12±0.53 cGy, 0.04±0.02 cGy, 0.13±0.23 cGy, 0.11±0.43 cGy, 0.10±0.04 cGy with overall mean dose of 0.08±0.1 cGy. Measured doses during treatment delivery, indicative of scattered and leakage dose, were 0.84±0.43 cGy, 1.3±0.4 cGy, 1.4±0.4 cGy, 0.18±0.48 cGy, 0.78±0.29 cGy, 0.27±0.08 cGy, 0.78±0.07 cGy with overall mean dose of 0.61±1.3 cGy.


This dosimeter can be used as supplementary unit to verify the doses. No change in the prescription is recommended based on nanoDots measurement. This study is on-going therefore we are presenting only mere number of patients. A large volume data will be presented after completion of the study with proper statistical analysis.